The OAM4558g phase II randomized study evaluated the activity and safety of onartuzumab plus erlotinib vs. placebo plus erlotinib in patients affected by recurrent NSCLC and suggested that only tumors with overexpression of c-MET benefit from the combined treatment [64]. Here, MET is linked to non-small cell lung carcinoma.